Needham Rates Tempus AI (TEM) Buy, $75 Price Target
Key Points
- Needham reiterated its Buy rating on Tempus AI, Inc. on October 23, 2026, holding its price target at $75.00.
- Needham's $75 price target implies 10.92% upside from Tempus AI, Inc.'s ($TEM) current $67.61 share price.
- Tempus AI recently traded at $67.61, sitting below its average analyst target while preparing for upcoming November earnings.
- Several institutional investors and company insiders recently adjusted their stakes in the healthcare technology firm.
Get Tempus AI text alerts
We text you when insiders, Congress, analysts or big funds move on $TEM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tempus AI, Inc. alert may contain errors. Disclosures
Needham reiterated its Buy rating on Tempus AI, Inc. [TEM] on October 23, 2026, keeping its price target unchanged at $75.00. The research note arrived as the healthcare technology firm's shares traded around $67.61.
TEM
Tempus AI, Inc.
Needham vs. the S&P 500
Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.
Needham's Call on Tempus AI, Inc.
In its research note on October 23, 2026, Needham kept a Buy rating on Tempus AI, Inc. alongside a $75.00 price target.
Other Institutional Activity in Tempus AI, Inc.
ARK Investment Management, LLC grew its holdings by 415,048 shares, ending with 10,022,634 shares worth about $677,680,376.0. BAILLIE GIFFORD & CO reduced its holdings by 459,284 shares, ending with 8,190,133 shares worth about $553,775,825.0. Softbank Group Corporation kept its holdings unchanged, ending with 5,405,406 shares worth about $365,486,515.0. Sumitomo Mitsui Trust Group, Inc. reduced its holdings by 237,070 shares, ending with 4,089,029 shares worth about $276,479,687.0. Amova Asset Management Americas Inc reduced its holdings by 237,070 shares, ending with 4,089,029 shares worth about $276,479,687.0.
Tempus AI, Inc. Stock Down 0.2%
Tempus AI, Inc. closed at $67.61 on October 23, 2026. The stock recently traded at $67.61, which is about equal to its event-day close. The shares sit below their 50-day moving average of $68.72 and above their 200-day moving average of $56.82.
$TEM price target
Tempus AI, Inc. daily closes and this analyst's $75 target. Not advice.
Recent Earnings
Tempus AI, Inc. reported trailing-twelve-month revenue of $1,432,018,944.0 with an EPS of $-1.44. The company has a net margin of -17.8% and a return on equity of -67.4%. Its next earnings report is scheduled for November 2, 2026.
Dividend
Tempus AI, Inc. currently pays no dividend.
Insider Buying and Selling at Tempus AI, Inc.
Officer Ryan Fukushima sold 30,846 shares on September 1, 2026, for a total value of $1,934,244.0. Director David R Epstein sold 250 shares on September 1, 2026, at an average price of $65.55 for a total value of $16,388.0. Chief Executive Officer Eric Paul Lefkofsky sold 250,000 shares on September 22, 2026, for a total value of $19,366,630.0. Officer Thomas Edward Schoenherr sold 10,281 shares on September 25, 2026, at an average price of $85.0 for a total value of $873,885.0.
Analysts Set New Price Targets
On September 21, 2026, Goldman Sachs initiated coverage on the stock with a Neutral rating and a $75.00 price target. On October 1, 2026, Guggenheim maintained its Buy rating and raised its target from $65.00 to $92.00. On October 12, 2026, Canaccord Genuity maintained its Buy rating and raised its target from $80.00 to $95.00. On October 14, 2026, JP Morgan maintained its Neutral rating and raised its target from $45.00 to $70.00. Wall Street currently tracks the stock with a consensus buy rating and a mean price target of $74.94 across 18 analyst opinions.
About Tempus AI, Inc.
Tempus AI, Inc. operates a healthcare technology platform in the United States that bridges clinical care and laboratory diagnostics. The company builds tools that connect doctors with genetic tests and multimodal data repositories to support patient care and research. This analyst update arrives as the firm prepares for its next quarterly financial update.
Bottom Line
Investors will look toward the company's upcoming earnings release on November 2, 2026, for fresh updates on financial growth. The rating highlights steady sentiment from research firms ahead of the report.
Related Filing Alerts
Source: Needham's rating change on $TEM (Oct 23, 2026). Written by software, not financial advice. How we make alerts